This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Novo Nordisk A/S Management Discusses Q2 2012 Results - Earnings Call Transcript

As usual, things may turn out completely differently than what we predict, usually not the case, I have to say, at least, when we speak about diabetes, but there are certain uncertainties associated with making predictions and please study this slide to know what the risk factors are. This is the highlight in fact from the front page of the press release that was sent out. Due to a very strong second quarter, we managed to come out the first half with a 12% local currency growth and because of the weakening of the Eurozone, that is translated into 17% growth in first half and in Danish kroner terms, the growth drivers are North America, International Operations, with 19% and 17%. In terms of product, it's Victoza and the modern insulins. They make up for the total growth. The rest is sort of wash up -- up and down. In the regulatory field, there's quite a few new things here. The regulatory process for Tresiba and Ryzodeg is moving along in all major markets. We have gotten a tentative AdCom date, November 8 in the U.S. and the process in Europe and Japan is moving along quite smoothly also.

We just announced a combination trial results where we combine a GLP-1 and an insulin. And as you could see from the data and from the release, they are actually doing what we had anticipated plus some, meaning, that this may present itself as a very attractive treatment option for a variety of different patient categories. And I'm sure we will be discussing the positioning and the potential of this type of combination drug during the Q&A. Then we have one news which is perhaps not so good. We saw in the last parts of the trial with vatreptacog alfa new factor VIIa analogue, potentially neutralizing antibody formation in one patient, and this needs to be started further. The way this is being assessed is in vitro, so we still need to see the efficacy data of whether any truly neutralizing effect clinically has taken place. We don't believe it has, but it's something we need to investigate further, but clearly, not good news. It just basically shows that when you toil around with biologics, if you go too far, you actually run the risk of eliciting antibody formation, and so this is an example of the associated risk with biopharmaceuticals. When we look at the financials, a very strong operating profit growth, 31%; diluted, 26% and we were able to lift our guidance for the year to 9% to 12% and 15% operating profit growth in local currencies. And with this, Kåre Schultz.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,949.59 -85.34 -0.47%
S&P 500 2,097.29 -3.11 -0.15%
NASDAQ 5,014.1020 +19.50 0.39%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs